闫克夏;谭文杰;张相民;王慧娟;李岩;阮力;

• 1:中国疾病预防控制中心病毒病预防控制所
• 2:中国疾病预防控制中心病毒病预防控制所
• 3:中国疾病预防控制中心病毒病预防控制所
• 4:中国疾病预防控制中心病毒病预防控制所

摘要(Abstract)：

为避免传统的SARS病毒中和试验需要操作活毒而存在的生物安全隐患,建立了基于假病毒系统、操作较安全的SARS中和试验技术平台。本研究应用高效表达SARS-CoV S(密码子优化的全长S蛋白,简称S)的真核表达载体(pVRC8304),与HIV慢病毒包装质粒(p CMV△8.2)及转移质粒(pHR′CMV EGFP)3个质粒载体系统共同转染人胚肾细胞293T,包装了SARS假病毒;通过SARS假病毒感染的RD-A细胞中标记基因EGFP表达的分析,确定SARS假病毒能有效进入细胞,建立了可在BSL-2级实验室操作的SARS病毒中和试验技术平台。用该技术平台对不同免疫血清进行了中和抗体分析,并比较了基于假病毒和基于SARS活病毒的中和试验效果。结果显示:SARS假病毒和SARS活病毒两个中和试验系统获得中和抗体滴度变化趋势一致,表明本研究构建的SARS假病毒可替代SARS活病毒用于建立操作上安全的SARS病毒中和试验技术平台。

关键词(KeyWords)： SARS-CoV;S蛋白;假病毒;中和试验

Abstract:

Keywords:

基金项目(Foundation): 国家863计划2007AA02Z464,病毒病预防控制所2005年SARS疾控专项经费

作者(Authors): 闫克夏;谭文杰;张相民;王慧娟;李岩;阮力;

参考文献(References)：

• [1]Rota P A,Oberste M S,Monroe S S,et al.Character-ization of a novel coronavirus associated with severe acuterespiratory syndrome[J].Science,2003,300(5624):1394-1399.
• [2]Orellana C.Laboratory-acquired SARS raises worries onbiosafety[J].Lancet Infect Dis,2004,4:64.
• [3]Wu H S,Chiu S C,Tseng T C,et al.Serologic and mo-lecular biologic methods for SARS-associated coronavirusinfection,Taiwan[J].Emerg Infect Dis,2004,10:304-310.
• [4]Xiao X,Chakraborti S,Dimitrov A S,et al.The SARS-CoV S glycoprotein:expression and functional character-ization[J].Biochem Biophys Res Commun,2003,312(4):1159-1164.
• [5]Jiang S,He Y,Liu S.SARS vaccine development[J].Emerg Infect Dis,2005,11(7):1016-1020.
• [6]Yang Z Y,Kong W P,Huang Y,et al.A DNA vaccineinduces SARS coronavirus neutralization and protectiveimmunity in mice[J].Nature,2004,428(6982):561-564.
• [7]Chen Z,Zhang L,Qin C,et al.Recombinant modifiedvaccinia virus Ankara expressing the spike glycoproteinof severe acute respiratory syndrome coronavirus inducesprotective neutralizing antibodies primarily targeting thereceptor binding region[J].J Virol,2005,79(5):2678-2688.
• [8]Naldini L,Blomer U,Gallay P,et al.In vivogene de-livery and stable transduction of nondividing cells by alentiviral vector[J].Science,1996,272:263-267.
• [9]Sanders D A.No false start for novel pseudotyped vec-tors[J].Curr Opin Biotechnol,2002,13:437-442.
• [10]Simmons G,Reeves J D,Rennekamp A J,et al.Char-acterization of severe acute respiratory syndrome-associ-ated coronavirus(SARS-CoV)spike glycoprotein-medi-ated viral entry[J].Proc Natl Acad Sci USA,2004,101:4240-4245.
• [11]Kim Y B,Lee M K,Han D P,et al.Development of asafe and rapid neutralization assay using murine leuke-mia virus pseudotyped with HIV type 1 envelope glyco-protein lacking the cytoplasmic domain[J].AIDS ResHum Retroviruses,2001,17:1715-1724.
• [12]Bartosch B,Bukh J,Meunier J C,et al.In vitroassayfor neutralizing antibody to hepatitis C virus:evidencefor broadly conserved neutralization epitopes[J].ProcNatl Acad Sci USA,2003,100:14199-14204.
• [13]Yang Z Y,Huang Y,Ganesh L,et al.pH-dependententry of severe acute respiratory syndrome coronavirusis mediated by the spike glycoprotein and enhanced bydendritic cell transfer through DC-SIGN[J].J Virol,2004,78:5642-5650.
• [14]Giroglou T,Cinatl J Jr,Rabenau H,et al.Retroviralvectors pseudotyped with severe acute respiratory syn-drome coronavirus A protein[J].J Virol,2004,78:9007-9015.
• [15]Hofmann H,Hattermann K,Marzi A,et al.S proteinof severe acute respiratory syndrome-associated corona-virus mediates entry into hepatoma cell lines and is tar-geted by neutralizing antibodies in infected patients[J].J Virol,2004,78:6134-6142.
• [16]Nie Y,Wang G,Shi X,et al.Neutralizing antibodiesin patients with severe acute respiratory syndrome-asso-ciated coronavirus infection[J].J Infect Dis,2004,190:1119-1126.
• [17]Nie Y,Wang P,Shi X,et al.Highly infectious SARS-CoV pseudotyped virus reveals the cell tropism and itscorrelation with receptor expression[J].Biochem Bio-phys Res Commun,2004,315:994-1000.
• [18]Hofmann H,Geier M,Marzi A,et al.Susceptibility toSARS coronavirus S protein-driven infection correlateswith expression of angiotensin converting enzyme 2 andinfection can be blocked by soluble receptor[J].Bio-chem Biophys Res Commun,2004,319:1216-1221.
• [19]Temperton N J,Chan P K,Simmons G,et al.Longitudi-nally profiling neutralizing antibody response to SARScoronavirus with pseudotypes[J].Emerg Infect Dis,2005,11(3):411-416.
• [20]闫克夏,SARS冠状病毒S与N蛋白抗原特性及其诊断应用的研究[D].中国疾病预防控制中心病毒病预防控制所博士学位论文,2006,北京
• [21]Marra M A,Jones S J,Astell C R,et al.The genomesequence of the SARS-associated coronavirus[J].Sci-ence,2003,300(5624):1399-1404.
• [22]Qiu M,Shi Y,Guo Z,et al.Antibody responses to in-dividual proteins of SARS coronavirus and their neutral-ization activities[J].Microbes Infect,2005,7(5-6):882-889.
• [23]Li W,Moore M J,Vasilieva N,et al.Angiotensin-con-verting enzyme 2 is a functional receptor for the SARScoronavirus[J].Nature,2003,426(6965):450-454.
• [24]He Y,Lu H,Siddiqui P,et al.Receptor-binding do-main of severe acute respiratory syndrome coronavirusspike protein contains multiple conformation-dependentepitopes that induce highly potent neutralizing antibod-ies[J].J Immunol,2005,174(8):4908-4915.